Vascular Hospitalization Rates and Costs in Patients With Peripheral Artery Disease in the United States

  • Elizabeth M. Mahoney
    From Saint Luke's Mid America Heart and Vascular Institute (E.M.M., K.W., K.S., D.J.C.), Kansas City, Mo; University of Missouri–-Kansas City School of Medicine (E.M.M., D.J.C.), Kansas City, Mo; the Center of Research on Psychology and Somatic Diseases (K.S.), Tilburg University, Tilburg, The Netherlands; the Division of Epidemiology and Community Health (H.H.K., S.D., A.T.H.), University of Minnesota School of Public Health, Minneapolis, Minn; INSERM U-698 (P.G.S.), Université Paris 7 and...
  • Kaijun Wang
    From Saint Luke's Mid America Heart and Vascular Institute (E.M.M., K.W., K.S., D.J.C.), Kansas City, Mo; University of Missouri–-Kansas City School of Medicine (E.M.M., D.J.C.), Kansas City, Mo; the Center of Research on Psychology and Somatic Diseases (K.S.), Tilburg University, Tilburg, The Netherlands; the Division of Epidemiology and Community Health (H.H.K., S.D., A.T.H.), University of Minnesota School of Public Health, Minneapolis, Minn; INSERM U-698 (P.G.S.), Université Paris 7 and...
  • Hong H. Keo
    From Saint Luke's Mid America Heart and Vascular Institute (E.M.M., K.W., K.S., D.J.C.), Kansas City, Mo; University of Missouri–-Kansas City School of Medicine (E.M.M., D.J.C.), Kansas City, Mo; the Center of Research on Psychology and Somatic Diseases (K.S.), Tilburg University, Tilburg, The Netherlands; the Division of Epidemiology and Community Health (H.H.K., S.D., A.T.H.), University of Minnesota School of Public Health, Minneapolis, Minn; INSERM U-698 (P.G.S.), Université Paris 7 and...
  • Sue Duval
    From Saint Luke's Mid America Heart and Vascular Institute (E.M.M., K.W., K.S., D.J.C.), Kansas City, Mo; University of Missouri–-Kansas City School of Medicine (E.M.M., D.J.C.), Kansas City, Mo; the Center of Research on Psychology and Somatic Diseases (K.S.), Tilburg University, Tilburg, The Netherlands; the Division of Epidemiology and Community Health (H.H.K., S.D., A.T.H.), University of Minnesota School of Public Health, Minneapolis, Minn; INSERM U-698 (P.G.S.), Université Paris 7 and...
  • Kim G. Smolderen
    From Saint Luke's Mid America Heart and Vascular Institute (E.M.M., K.W., K.S., D.J.C.), Kansas City, Mo; University of Missouri–-Kansas City School of Medicine (E.M.M., D.J.C.), Kansas City, Mo; the Center of Research on Psychology and Somatic Diseases (K.S.), Tilburg University, Tilburg, The Netherlands; the Division of Epidemiology and Community Health (H.H.K., S.D., A.T.H.), University of Minnesota School of Public Health, Minneapolis, Minn; INSERM U-698 (P.G.S.), Université Paris 7 and...
  • David J. Cohen
    From Saint Luke's Mid America Heart and Vascular Institute (E.M.M., K.W., K.S., D.J.C.), Kansas City, Mo; University of Missouri–-Kansas City School of Medicine (E.M.M., D.J.C.), Kansas City, Mo; the Center of Research on Psychology and Somatic Diseases (K.S.), Tilburg University, Tilburg, The Netherlands; the Division of Epidemiology and Community Health (H.H.K., S.D., A.T.H.), University of Minnesota School of Public Health, Minneapolis, Minn; INSERM U-698 (P.G.S.), Université Paris 7 and...
  • Gabriel Steg
    From Saint Luke's Mid America Heart and Vascular Institute (E.M.M., K.W., K.S., D.J.C.), Kansas City, Mo; University of Missouri–-Kansas City School of Medicine (E.M.M., D.J.C.), Kansas City, Mo; the Center of Research on Psychology and Somatic Diseases (K.S.), Tilburg University, Tilburg, The Netherlands; the Division of Epidemiology and Community Health (H.H.K., S.D., A.T.H.), University of Minnesota School of Public Health, Minneapolis, Minn; INSERM U-698 (P.G.S.), Université Paris 7 and...
  • Deepak L. Bhatt
    From Saint Luke's Mid America Heart and Vascular Institute (E.M.M., K.W., K.S., D.J.C.), Kansas City, Mo; University of Missouri–-Kansas City School of Medicine (E.M.M., D.J.C.), Kansas City, Mo; the Center of Research on Psychology and Somatic Diseases (K.S.), Tilburg University, Tilburg, The Netherlands; the Division of Epidemiology and Community Health (H.H.K., S.D., A.T.H.), University of Minnesota School of Public Health, Minneapolis, Minn; INSERM U-698 (P.G.S.), Université Paris 7 and...
  • Alan T. Hirsch
    From Saint Luke's Mid America Heart and Vascular Institute (E.M.M., K.W., K.S., D.J.C.), Kansas City, Mo; University of Missouri–-Kansas City School of Medicine (E.M.M., D.J.C.), Kansas City, Mo; the Center of Research on Psychology and Somatic Diseases (K.S.), Tilburg University, Tilburg, The Netherlands; the Division of Epidemiology and Community Health (H.H.K., S.D., A.T.H.), University of Minnesota School of Public Health, Minneapolis, Minn; INSERM U-698 (P.G.S.), Université Paris 7 and...

書誌事項

公開日
2010-11
DOI
  • 10.1161/circoutcomes.109.930735
公開者
Ovid Technologies (Wolters Kluwer Health)

この論文をさがす

説明

<jats:sec> <jats:title>Background—</jats:title> <jats:p> Peripheral artery disease (PAD) is common and imposes a high risk of major systemic and limb ischemic events. The <jats:italic>RE</jats:italic> duction of <jats:italic>A</jats:italic> therothrombosis for <jats:italic>C</jats:italic> ontinued <jats:italic>H</jats:italic> ealth (REACH) Registry is an international prospective registry of patients at risk of atherothrombosis caused by established arterial disease or the presence of ≥3 atherothrombotic risk factors. </jats:p> </jats:sec> <jats:sec> <jats:title>Methods and Results—</jats:title> <jats:p> We compared the 2-year rates of vascular-related hospitalizations and associated costs in US patients with established PAD across patient subgroups. Symptomatic PAD at enrollment was identified on the basis of current intermittent claudication with an ankle-brachial index (ABI) <0.90 or a history of lower-limb revascularization or amputation. Asymptomatic PAD was diagnosed on the basis of an enrollment ABI <0.90 in the absence of symptoms. Overall, 25 763 of the total 68 236–patient REACH cohort were enrolled from US sites; 2396 (9.3%) had symptomatic and 213 (0.8%) had asymptomatic PAD at baseline. One- and cumulative 2-year follow-up data were available for 2137 (82%) and 1677 (64%) of US REACH patients with either symptomatic or asymptomatic PAD, respectively. At 2 years, mean cumulative hospitalization costs, per patient, were $7445, $7000, $10 430, and $11 693 for patients with asymptomatic PAD, a history of claudication, lower-limb amputation, and revascularization, respectively ( <jats:italic>P</jats:italic> =0.007). A history of peripheral intervention (lower-limb revascularization or amputation) was associated with higher rates of subsequent procedures at both 1 and 2 years. </jats:p> </jats:sec> <jats:sec> <jats:title>Conclusions—</jats:title> <jats:p>The economic burden of PAD is high. Recurring hospitalizations and repeat revascularization procedures suggest that neither patients, physicians, nor healthcare systems should assume that a first admission for a lower-extremity PAD procedure serves as a permanent resolution of this costly and debilitating condition.</jats:p> </jats:sec>

収録刊行物

被引用文献 (4)*注記

もっと見る

詳細情報 詳細情報について

問題の指摘

ページトップへ